Xofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of increased bone metabolism, which are associated with bone metastases. Xofigo has a long enough half-life of 11.43 days from synthesis for manufacturing and distribution, but the serum half-life of Xofigo is short, with around 0.5% remaining in the blood after 24 hours.
4 Drug Overview
5 Product Profiles
5 Xofigo : Prostate cancer
LIST OF FIGURES
10 Figure 1: Xofigo for prostate cancer – SWOT analysis
11 Figure 11: DCVAC/PCa for prostate cancer – SWOT analysis
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of Xofigo for prostate cancer
14 Figure 4: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Xofigo drug profile
7 Table 2: Xofigo Phase III data in prostate cancer
9 Table 3: Xofigo Phase III trials in prostate cancer
15 Table 4: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.